B cells occupy a vital role in the functioning of the immune system, working in tandem with T
cells to either suppress or promote tumor growth within the tumor microenvironment (TME) …

As widely acknowledged, 40–50% of all melanoma patients harbour an activating BRAF
mutation (mostly BRAF V600E). The identification of the RAS–RAF–MEK–ERK (MAP kinase) …

PURPOSE An ASCO provisional clinical opinion offers timely clinical direction to ASCO's
membership following publication or presentation of potentially practice-changing data from …

Despite significant progress in clinical management, drug resistance remains a major
obstacle. Recent research based on protein degradation to restrain drug resistance has …

Abstract The Cancer Genome Atlas (TCGA) and the Cancer Cell Line Encyclopedia (CCLE)
are foundational resources in cancer research, providing extensive molecular and …

BRAF mutations are relatively common in many cancers, particularly melanoma, colorectal
cancer, and thyroid cancer and to a lesser extent in lung cancer. These mutations can be …

PURPOSE TAPUR is a phase II basket trial evaluating the antitumor activity of commercially
available targeted agents in patients with advanced cancer and genomic alterations known …

Simple Summary Immune checkpoint inhibitors and BRAF/MEK inhibitors are the
cornerstone of treatment for melanoma; however, primary and acquired resistance to these …

In the last decade, immunotherapy and target therapy have revolutionized the prognosis of
patients with BRAF-V600 mutation-positive metastatic melanoma. To date, three different …

Despite significant progress in the development of treatment options, melanoma remains a
leading cause of death due to skin cancer. Advances in our understanding of the genetic …